SynthesisVirology journal2026
Efficacy of direct-acting antiviral regimens for acute HCV infection: a systematic review and meta-analysis.
Synthesis in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute and recently acquired hepatitis C virus (HCV) infection clusters in men who have sex with men living with HIV and in people who inject drugs, where early cure benefits both the individual and transmission control. The best interferon-free dual direct-acting antiviral (DAA) regimen and treatment duration, including short courses, remain undefined.
methodsMEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched to 1 July 2026 for studies of interferon-free dual-DAA therapy in acute or recently acquired HCV reporting SVR12. Each study was appraised as a single-arm case series, and proportions were pooled by random-intercept logistic regression. Pre-specified subgroups were regimen, treatment duration, study design, and HIV status.
resultsFourteen studies (19 single-arm analysis units; 1078 treated patients) were included. Pooled SVR12 was 97.7% (95% CI 94.7-99.1; 1043/1078; I² = 30.4%). SVR12 rates increased with treatment duration, from 84.8% (74.1-91.6) at 4 weeks and 91.7% (86.2-95.1) at 6 weeks to 99.4% (97.5-99.9) at 8 weeks and 97.4% (91.7-99.2) at 12 weeks (between-subgroup p < 0.001), whereas it did not differ by regimen (p = 0.608), study design (p = 0.764), or HIV status (p = 0.975). The pooled estimate was stable across sensitivity analyses (trials only, exclusion of the high-risk study, and leave-one-out).
conclusionDual-DAA therapy was associated with a high pooled SVR12 in acute and recently acquired HCV, with cure differing by treatment duration. These findings support early treatment and favour a course of at least eight weeks. Given the predominantly single-arm evidence and the partial confounding of regimen with duration, randomised duration-comparison trials are needed to confirm the optimal short-course strategy.
Indexed as
Identifiers
42850633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.